Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

7,844 total articles

Talen Energy Announces Pricing of Senior Notes

Talen Energy Announces Pricing of Senior Notes

Talen Energy Corporation has priced $4 billion in senior notes due 2031 and 2033 to finance its acquisition of 2,451 MW of power generation capacity and redeem existing higher-coupon debt. The move supports the company's expansion with additional fossil and nuclear assets, strengthening its position in the U.S. power generation market.

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

BioXcel Therapeutics announced a virtual event focused on their commercial launch plan for IGALMI®, targeting the treatment of acute agitation associated with bipolar disorder and schizophrenia in the at-home setting, ahead of the November 14 PDUFA date. Market assessment highlights a significant opportunity with up to 86 million annual addressable…

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026

Pyxis Oncology announced new preclinical data demonstrating that its lead candidate, micvotabart pelidotin (MICVO), a novel antibody-drug conjugate, shows significant anti-tumor activity as monotherapy and synergistic effects when combined with anti-PD-1 therapy in a head and neck squamous cell carcinoma (HNSCC) model. These findings support ongoin…

AOI Expands Its Houston-Area Footprint to 900,000 Square Feet to Increase Capacity and Support Future Growth

AOI Expands Its Houston-Area Footprint to 900,000 Square Feet to Increase Capacity and Support Future Growth

Applied Optoelectronics, Inc. is expanding its Houston-area facilities by adding two adjacent buildings in Pearland, Texas, increasing its manufacturing capacity by about 388,000 square feet. This move supports the company’s ambitious 2027 capacity targets and positions AOI to scale production of high-speed optical transceivers and laser fabricatio…

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals announced the presentation of multiple preclinical data posters at the 2026 AACR Annual Meeting demonstrating the potential of their drug candidate rinzimetostat, an allosteric PRC2 inhibitor, to treat prostate cancer, including treatment-resistant forms. The data indicates strong antitumor activity across prostate cancer model…

Intchains Group Limited Provides Staking Activities Update; Advances Strategic Transformation with AI-Enabled Operating Model to Enhance Efficiency and Productivity

Intchains Group Limited Provides Staking Activities Update; Advances Strategic Transformation with AI-Enabled Operating Model to Enhance Efficiency and Productivity

Intchains Group Limited reports active staking of over 8,000 ETH on multiple platforms to optimize returns from its treasury assets, while undertaking a strategic transformation by embedding AI-enabled tools across its operations to enhance efficiency, streamline costs, and drive innovation in its altcoin mining and Web3 infrastructure services bus…

4DMT Announces New Employment Inducement Grants

4DMT Announces New Employment Inducement Grants

4D Molecular Therapeutics announced equity inducement grants of 67,600 Restricted Stock Units to five new non-executive employees as part of its 2025 Employment Inducement Award Plan. The grants aim to attract talent to support the company’s development of late-stage gene therapies targeting retinal diseases and cystic fibrosis.

USA Rare Earth Appoints Chaitan Kansal as Chief Commercial Officer

USA Rare Earth Appoints Chaitan Kansal as Chief Commercial Officer

USA Rare Earth has appointed Chaitan Kansal as Chief Commercial Officer in a new role to lead global commercial strategy, accelerate customer engagement, and secure long-term offtake agreements. This comes as the company moves from development to active production with recent milestones including commissioning of commercial magnet production and st…

Vera Bradley Terminates Existing Shareholder Rights Plan

Vera Bradley Terminates Existing Shareholder Rights Plan

Vera Bradley, Inc. announced the termination of its existing shareholder rights plan effective April 17, 2026, earlier than the originally scheduled October 11, 2026 expiration. The Board cites a reassessment of control risks through market accumulations and believes the plan is no longer necessary at this time. The company remains committed to pro…

Zhihu Inc. Files Its 2025 Annual Report on Form 20-F

Zhihu Inc. Files Its 2025 Annual Report on Form 20-F

Zhihu Inc., a leading online content community in China, has filed its annual report for the fiscal year ended December 31, 2025, on Form 20-F with the U.S. Securities and Exchange Commission. The report includes audited consolidated financial statements and is accessible on the company’s investor relations website. Zhihu offers free hard copies to…

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Revolution Medicines, a Nasdaq-listed late-stage clinical oncology company specializing in RAS-addicted cancer therapies, completed concurrent upsized public offerings of common stock and convertible senior notes totaling approximately $2.2 billion. The net proceeds will be utilized to support research and development, potential commercialization, …

Hingham Savings Reports First Quarter 2026 Results

Hingham Savings Reports First Quarter 2026 Results

Hingham Institution for Savings reported first quarter 2026 earnings showing a 60.2% decrease in GAAP net income per share compared to last year, primarily due to a net loss on equity securities. However, Core net income, excluding equity securities gains/losses, rose 72.3%. Total assets grew slightly to $4.55 billion with retail and commercial dep…

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting

Olema Oncology announced compelling preclinical data for its breast cancer therapies palazestrant and OP-3136 at the 2026 AACR Annual Meeting. Palazestrant, a complete estrogen receptor antagonist and degrader, demonstrated robust anti-tumor activity by recruiting corepressor NCoR1 to fully block estrogen receptor activity. Combined with OP-3136, a…

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting

Cardiff Oncology presented preclinical data demonstrating that its oral PLK1 inhibitor, onvansertib, combined with trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate, shows robust antitumor activity and overcomes resistance in HER2-low breast cancer models. The combination produced high tumor regression rates and good tolerabil…

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2

Xilio Therapeutics announced new preclinical data for XTX601, a masked T cell engager aimed at selectively targeting the tumor-associated antigen CLDN18.2 in gastric, pancreatic, and esophageal cancers. The data demonstrated tumor-selective activation, potent anti-tumor activity in multiple models, and a favorable safety profile in non-human primat…

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities

Acrivon Therapeutics announced preclinical findings demonstrating strong synergistic effects of its lead cancer drug candidates ACR-368 and ACR-2316 when combined with anti-PD-L1 immune checkpoint inhibitors and antibody-drug conjugate (ADC) payloads, specifically Topoisomerase 1 inhibitors. These results support the potential for developing frontl…

Zhihu Inc. Publishes 2025 Environmental, Social and Governance Report

Zhihu Inc. Publishes 2025 Environmental, Social and Governance Report

Zhihu Inc., a leading Chinese online content community listed on NYSE (ZH) and HKEX (2390), has published its 2025 Environmental, Social, and Governance Report. The Report details Zhihu's sustainability efforts, corporate culture development, and commitment to creating long-term value for stakeholders. The document is accessible in both English and…

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Repligen Corporation has inaugurated its third global Training & Innovation Center in Breda, Netherlands, expanding its global customer support network. The new center at the OPUS pre-packed chromatography columns manufacturing facility offers hands-on experiences with Repligen's diverse bioprocessing technologies. This expansion complements existi…

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Submits Orphan Drug Designation Application to U.S. FDA for SkinJect® in Gorlin Syndrome

Medicus Pharma Ltd. has submitted an Orphan Drug Designation application to the FDA for SkinJect®, a localized treatment for basal cell carcinoma in patients with Gorlin Syndrome, a rare genetic disorder causing frequent skin cancers. The move targets a high unmet medical need with no approved therapies, aiming to offer a repeatable, non-surgical o…

PMGC Holdings, Inc. (Nasdaq: ELAB) Secures $40 Million Equity Purchase Facility Agreement: Announces Ability To Accelerate M&A Strategy Currently Focused on Acquiring Aerospace and Defense Manufacturing Companies

PMGC Holdings, Inc. (Nasdaq: ELAB) Secures $40 Million Equity Purchase Facility Agreement: Announces Ability To Accelerate M&A Strategy Currently Focused on Acquiring Aerospace and Defense Manufacturing Companies

PMGC Holdings, Inc. announced a $40 million equity purchase facility agreement with an institutional investor, providing flexible capital to support its roll-up strategy targeting U.S.-based precision manufacturing companies in aerospace, defense, and industrial sectors. The company aims to grow through acquisitions and operational investments, cap…

Lincoln Educational Services Corporation Schedules First Quarter 2026 Earnings Release And Conference Call

Lincoln Educational Services Corporation Schedules First Quarter 2026 Earnings Release And Conference Call

Lincoln Educational Services Corporation announced the date and details for its first quarter 2026 earnings release and conference call, scheduled for May 11, 2026. The company will provide a webcast and teleconference access to discuss its financial results and business updates. Lincoln is a leading provider of career-oriented post-secondary educa…